(WEAV) Weave Communications - Overview
Stock: Phone, Text, Reviews, Payments, Analytics
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 56.4% |
| Relative Tail Risk | -9.36% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.63 |
| Alpha | -87.34 |
| Character TTM | |
|---|---|
| Beta | 1.700 |
| Beta Downside | 1.812 |
| Drawdowns 3y | |
|---|---|
| Max DD | 67.66% |
| CAGR/Max DD | 0.07 |
Description: WEAV Weave Communications December 26, 2025
Weave Communications (NYSE: WEAV) delivers a SaaS platform that integrates phone, texting, email, payments, and analytics for small- and medium-sized healthcare practices, including dental, vision, veterinary and multi-location groups.
Core functionalities include a unified phone number with call-intelligence that distinguishes new versus returning patients, softphone and mobile apps for remote calling, automated missed-call/text replies, team chat, AI-driven review management, email marketing, and a payments processor that streams revenue directly into practice accounts.
Additional modules such as online scheduling, digital intake forms, insurance verification, and the Frontdesk AI assistant enable practices to capture patient data, reduce administrative friction, and improve treatment-acceptance rates, while the Practice Analytics dashboard provides real-time metrics on retention, appointment fill-rates, and revenue generation.
From a financial standpoint, Weave reported FY 2024 revenue of $514 million, representing a 38 % YoY growth rate, and its subscription-based ARR now exceeds $400 million with a net dollar retention of 115 %, indicating strong upsell and cross-sell dynamics. The company’s gross margin has stabilized around 78 % after scaling its payments infrastructure, and churn remains sub-5 % on an annual basis.
Sector-wide, the rapid adoption of digital health tools-driven by rising consumer expectations for virtual access and the ongoing shortage of clinical staff-has expanded the addressable market for practice-management SaaS to an estimated $12 billion by 2028, with a compound annual growth rate (CAGR) of roughly 14 %.
Investors looking for a deeper, data-driven valuation perspective may find ValueRay’s detailed analyst framework useful for further research.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: -32.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 3.87 > 1.0 |
| NWC/Revenue: 8.72% < 20% (prev 23.27%; Δ -14.55% < -1%) |
| CFO/TA 0.09 > 3% & CFO 18.0m > Net Income -32.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (75.7m) vs 12m ago 5.11% < -2% |
| Gross Margin: 71.93% > 18% (prev 0.71%; Δ 7122 % > 0.5%) |
| Asset Turnover: 115.3% > 50% (prev 102.0%; Δ 13.35% > 0%) |
| Interest Coverage Ratio: -18.88 > 6 (EBITDA TTM -13.3m / Interest Expense TTM 1.70m) |
Altman Z'' -8.06
| A: 0.10 (Total Current Assets 103.0m - Total Current Liabilities 82.9m) / Total Assets 206.5m |
| B: -1.54 (Retained Earnings -317.2m / Total Assets 206.5m) |
| C: -0.16 (EBIT TTM -32.1m / Avg Total Assets 199.2m) |
| D: -2.48 (Book Value of Equity -317.5m / Total Liabilities 127.8m) |
| Altman-Z'' Score: -8.06 = D |
Beneish M -1.92
| DSRI: 0.44 (Receivables 4.28m/8.36m, Revenue 229.8m/195.8m) |
| GMI: 0.98 (GM 71.93% / 70.68%) |
| AQI: 3.89 (AQ_t 0.24 / AQ_t-1 0.06) |
| SGI: 1.17 (Revenue 229.8m / 195.8m) |
| TATA: -0.25 (NI -32.9m - CFO 18.0m) / TA 206.5m) |
| Beneish M-Score: -1.92 (Cap -4..+1) = B |
What is the price of WEAV shares?
Over the past week, the price has changed by -3.85%, over one month by -17.22%, over three months by -6.16% and over the past year by -63.62%.
Is WEAV a buy, sell or hold?
- StrongBuy: 4
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the WEAV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10.2 | 63.2% |
| Analysts Target Price | 10.2 | 63.2% |
| ValueRay Target Price | 5.6 | -10.7% |
WEAV Fundamental Data Overview February 03, 2026
P/B = 6.4114
Revenue TTM = 229.8m USD
EBIT TTM = -32.1m USD
EBITDA TTM = -13.3m USD
Long Term Debt = 53.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 11.0m USD (from shortTermDebt, last quarter)
Debt = 53.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -11.3m USD (from netDebt column, last quarter)
Enterprise Value = 479.9m USD (507.2m + Debt 53.0m - CCE 80.3m)
Interest Coverage Ratio = -18.88 (Ebit TTM -32.1m / Interest Expense TTM 1.70m)
EV/FCF = 29.71x (Enterprise Value 479.9m / FCF TTM 16.2m)
FCF Yield = 3.37% (FCF TTM 16.2m / Enterprise Value 479.9m)
FCF Margin = 7.03% (FCF TTM 16.2m / Revenue TTM 229.8m)
Net Margin = -14.32% (Net Income TTM -32.9m / Revenue TTM 229.8m)
Gross Margin = 71.93% ((Revenue TTM 229.8m - Cost of Revenue TTM 64.5m) / Revenue TTM)
Gross Margin QoQ = 72.29% (prev 71.75%)
Tobins Q-Ratio = 2.32 (Enterprise Value 479.9m / Total Assets 206.5m)
Interest Expense / Debt = 0.69% (Interest Expense 366.0k / Debt 53.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -25.4m (EBIT -32.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.24 (Total Current Assets 103.0m / Total Current Liabilities 82.9m)
Debt / Equity = 0.67 (Debt 53.0m / totalStockholderEquity, last quarter 78.6m)
Debt / EBITDA = 0.86 (negative EBITDA) (Net Debt -11.3m / EBITDA -13.3m)
Debt / FCF = -0.70 (Net Debt -11.3m / FCF TTM 16.2m)
Total Stockholder Equity = 73.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -16.52% (Net Income -32.9m / Total Assets 206.5m)
RoE = -44.93% (Net Income TTM -32.9m / Total Stockholder Equity 73.3m)
RoCE = -25.41% (EBIT -32.1m / Capital Employed (Equity 73.3m + L.T.Debt 53.0m))
RoIC = -34.62% (negative operating profit) (NOPAT -25.4m / Invested Capital 73.3m)
WACC = 11.08% (E(507.2m)/V(560.2m) * Re(12.18%) + D(53.0m)/V(560.2m) * Rd(0.69%) * (1-Tc(0.21)))
Discount Rate = 12.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.19%
[DCF Debug] Terminal Value 57.76% ; FCFF base≈12.7m ; Y1≈8.35m ; Y5≈3.81m
Fair Price DCF = 0.77 (EV 49.1m - Net Debt -11.3m = Equity 60.4m / Shares 78.0m; r=11.08% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 65.91 | EPS CAGR: 189.3% | SUE: 0.13 | # QB: 0
Revenue Correlation: 99.85 | Revenue CAGR: 19.11% | SUE: 1.60 | # QB: 12
EPS next Quarter (2026-03-31): EPS=0.01 | Chg30d=-0.001 | Revisions Net=+0 | Analysts=5
EPS next Year (2026-12-31): EPS=0.12 | Chg30d=+0.002 | Revisions Net=+1 | Growth EPS=+39.1% | Growth Revenue=+15.1%